AJR Am J Roentgenol
- JIRARAYAPONG J, Portnow LH, Chikarmane SA, Lan Z, et al
High Peritumoral and Intratumoral T2 Signal Intensity in HER2+ Breast Cancers on
Preneoadjuvant Breast MRI: Assessment of Associations With Histopathologic
Characteristics.
AJR Am J Roentgenol. 2023 Dec 20. doi: 10.2214/AJR.23.30280.
- NGUYEN DL, Greenwood HI, Rahbar H, Grimm LJ, et al
Evolving Treatment Paradigms for Low-Risk Ductal Carcinoma In Situ: Imaging
Needs.
AJR Am J Roentgenol. 2023 Dec 13. doi: 10.2214/AJR.23.30503.
Am J Epidemiol
- PAPANTONIOU K, Hansen J
Cohort Studies Versus Case-Control Studies on Night-Shift Work and Cancer Risk:
The Importance of Exposure Assessment.
Am J Epidemiol. 2024;193:577-579.
Ann Surg Oncol
- CHU JJ, Tadros AB, Vingan PS, Assel MJ, et al
Remote Symptom Monitoring with Clinical Alerts Following Mastectomy: Do Early
Symptoms Predict 30-Day Surgical Complications.
Ann Surg Oncol. 2024;31:3377-3386.
- GREENE AJE, Davis J, Moon J, Dubin I, et al
Determination of Factors Associated with Upstage in Atypical Ductal Hyperplasia
to Identify Low-Risk Patients Where Active Surveillance May be an Alternative.
Ann Surg Oncol. 2024;31:3177-3185.
- XIONG M, Young AT, Fernandez A, Jones JS, et al
Understanding Breast Cancer Surgery Through Tiktok: an Analysis of Video Content
and Viewer Engagement.
Ann Surg Oncol. 2024 Apr 9. doi: 10.1245/s10434-024-15268.
BMC Cancer
- LIU Z, Li J, Zhao F, Ren D, et al
Long-term survival after neoadjuvant therapy for triple-negative breast cancer
under different treatment regimens: a systematic review and network
meta-analysis.
BMC Cancer. 2024;24:440.
Br J Cancer
- ALEXANDER J, Schipper K, Nash S, Brough R, et al
Pathway-based signatures predict patient outcome, chemotherapy benefit and
synthetic lethal dependencies in invasive lobular breast cancer.
Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
- ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
Neratinib could be effective as monotherapy or in combination with trastuzumab in
HER2-low breast cancer cells and organoid models.
Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
Breast Cancer
- TOKUDA PJK, Mitsuyoshi T, Ono Y, Kishi T, et al
Acute adverse events of ultra-hypofractionated whole-breast irradiation after
breast-conserving surgery for early breast cancer in Japan: an interim analysis
of the multi-institutional phase II UPBEAT study.
Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577.
- DE MOURA A, Loirat D, Vaillant S, Korbi S, et al
Sacituzumab govitecan in metastatic triple-negative breast cancer patients
treated at Institut Curie Hospitals: efficacy, safety, and impact of brain
metastases.
Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565.
- SUZUKI K, Morishita S, Nakano J, Okayama T, et al
Association between quality of life and mortality risk in patients with breast
cancer: a systematic review and meta-analysis.
Breast Cancer. 2024 Apr 9. doi: 10.1007/s12282-024-01581.
- WATANABE A, Tsunashima R, Kato C, Kitano S, et al
Investigation of recurrence prediction ability of EndoPredict((R)) using microarray
data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and
indication expansion of EndoPredict((R)) from microarray data from fresh-frozen to
FFPE
Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573.
Breast Cancer (Dove Med Press)
- WANG S, Chen Y, Li W, Hao C, et al
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast
Cancer Patients.
Breast Cancer (Dove Med Press). 2024;16:163-179.
Breast Cancer Res
- KARIHTALA P, Leivonen SK, Puistola U, Urpilainen E, et al
Serum protein profiling reveals an inflammation signature as a predictor of early
breast cancer survival.
Breast Cancer Res. 2024;26:61.
- ZHANG W, Song X, Jin Z, Zhang Y, et al
U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the
translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.
Breast Cancer Res. 2024;26:60.
- WOOLPERT KM, Schmidt JA, Ahern TP, Hjorth CF, et al
Clinical factors associated with patterns of endocrine therapy adherence in
premenopausal breast cancer patients.
Breast Cancer Res. 2024;26:59.
Breast Cancer Res Treat
- ALLSOPP RC, Guo Q, Page K, Bhagani S, et al
Circulating tumour DNA dynamics during alternating chemotherapy and hormonal
therapy in metastatic breast cancer: the ALERT study.
Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07316.
- RUKHSANA, Supty AT, Hussain M, Lee Y, et al
STK3 higher expression association with clinical characteristics in intrinsic
subtypes of breast cancer invasive ductal carcinoma patients.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07248.
- WANG Y, Sun W, Karlsson E, Kang Lovgren S, et al
Clinical evaluation of deep learning-based risk profiling in breast cancer
histopathology and comparison to an established multigene assay.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07303.
- FORTNER RT, Brantley KD, Tworoger SS, Tamimi RM, et al
Recreational physical activity and breast cancer risk by menopausal status and
tumor hormone receptor status: results from the Nurses' Health Studies.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-023-07238.
- BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al
Correction: Surgery of the primary tumor in patients with de novo metastatic
breast cancer: a nationwide population-based retrospective cohort study in
Belgium.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275.
Cancer Cell
- LIN CJ, Jin X, Ma D, Chen C, et al
Genetic interactions reveal distinct biological and therapeutic implications in
breast cancer.
Cancer Cell. 2024;42:701-719.
Cancer Lett
- WANG J, Fan P, Shen P, Fan C, et al
XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation
in breast cancer.
Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
- LI K, Lin H, Liu A, Qiu C, et al
SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in
triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of
PIMREG.
Cancer Lett. 2024;590:216842.
Cancer Res
- ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast
Cancer.
Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
Clin Breast Cancer
- MICHAELS E, Chen N, Nanda R
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
Clin Breast Cancer. 2024 Mar 6:S1526-8209(24)00061.
- D'ALESSANDRO GS, Munhoz AM, Takeuchi FM, Povedano A, et al
Is Immediate Breast Reconstruction With a Latissimus Dorsi Myocutaneous Flap Safe
for Starting Adjuvant Chemotherapy in Patients With Breast Cancer?
Clin Breast Cancer. 2024 Mar 10:S1526-8209(24)00076.
Clin Exp Metastasis
- BHAT V, Piaseczny M, Goodale D, Patel U, et al
Lung-derived soluble factors support stemness/plasticity and metastatic behaviour
of breast cancer cells via the FGF2-DACH1 axis.
Clin Exp Metastasis. 2024 Apr 6. doi: 10.1007/s10585-024-10284.
Curr Treat Options Oncol
- MOLINELLI C, Jacobs F, Nader-Marta G, Borea R, et al
Ovarian Suppression: Early Menopause and Late Effects.
Curr Treat Options Oncol. 2024;25:523-542.
Exp Cell Res
- SHOME R, Sen P, Sarkar S, Ghosh SS, et al
Single-cell transcriptomics reveals the intra-tumoral heterogeneity and
SQSTM1/P62 and Wnt/beta-catenin mediated epithelial to mesenchymal transition and
stemness of triple-negative breast cancer.
Exp Cell Res. 2024 Apr 5:114032. doi: 10.1016/j.yexcr.2024.114032.
Gene
- DEHGHANIAN F, Ghahnavieh LE, Nilchi AN, Khalilian S, et al
Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk.
Gene. 2024;916:148424.
- VOSOOGHI R, Motavalizadehkakhky A, Mansouri A, Mehrzad J, et al
Investigating the effect of hesperetin on estrogen receptor alpha (ERalpha)
expression, phosphorylation and activity in MCF-7 cells.
Gene. 2024;911:148357.
Int J Radiat Oncol Biol Phys
- LOVING BA, Almahariq MF, Sivapalan S, Levitin R, et al
Newly Diagnosed Mental Health Disorders in Patients with Breast Cancer Receiving
Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2024 Apr 4:S0360-3016(24)00445.
J Clin Invest
- JOHNSON N
Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
J Clin Invest. 2024;134:e179325.
J Clin Oncol
- RIOS-HOYO A, Cobain E, Huppert LA, Beitsch PD, et al
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human
Epidermal Growth Factor 2-Negative Breast Cancer.
J Clin Oncol. 2024 Apr 9:JCO2302614. doi: 10.1200/JCO.23.02614.
J Natl Cancer Inst
- OMOLEYE OJ, Esserman LJ, Olopade OI
RE: Supplemental magnetic resonance imaging plus mammography compared with
magnetic resonance imaging or mammography by extent of breast density.
J Natl Cancer Inst. 2024;116:627-628.
- VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
Familial uveal melanoma and other tumors in 25 families with monoallelic germline
MBD4 variants.
J Natl Cancer Inst. 2024;116:580-587.
JAMA
- NAROD SA
Breast Cancer and Pregnancy in Young BRCA Carriers.
JAMA. 2024;331:1233-1234.
- BLONDEAUX E, Partridge AH, Lambertini M
Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
JAMA. 2024;331:1234.
Lancet
- PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
3-year invasive disease-free survival with chemotherapy de-escalation using an
(18)F-FDG-PET-based, pathological complete response-adapted strategy in
HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2
trial.
Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
- EARL HM
Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
Lancet Oncol
- VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III
HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
Mol Ther Oncol
- LIAO Q, Zhang R, Ou Z, Ye Y, et al
TROP2 is highly expressed in triple-negative breast cancer CTCs and is a
potential marker for epithelial mesenchymal CTCs.
Mol Ther Oncol. 2024;32:200762.
N Engl J Med
- DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
N Engl J Med. 2024;390:1163-1175.
Nature
- ABRAHAM JE, Pinilla K, Dayimu A, Grybowicz L, et al
The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer.
Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07384.
NPJ Breast Cancer
- BAR Y, Keenan JC, Niemierko A, Medford AJ, et al
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA)
analysis of patients with metastatic breast cancer.
NPJ Breast Cancer. 2024;10:27.
Oncogene
- BOTTONI L, Minetti A, Realini G, Pio E, et al
NRF2 activation by cysteine as a survival mechanism for triple-negative breast
cancer cells.
Oncogene. 2024 Apr 10. doi: 10.1038/s41388-024-03025.
PLoS One
- ALHASSAN AM
An improved breast cancer classification with hybrid chaotic sand cat and Remora
Optimization feature selection algorithm.
PLoS One. 2024;19:e0300622.
- SLOJEWSKA K, Galbarczyk A, Klimek M, Tubek-Krokosz A, et al
Higher number of steps is related to lower endogenous progesterone but not
estradiol levels in women.
PLoS One. 2024;19:e0299580.
Radiol Artif Intell
- LARSEN M, Olstad CF, Lee CI, Hovda T, et al
Performance of an AI System for Breast Cancer Detection on Screening Mammograms
from BreastScreen Norway.
Radiol Artif Intell. 2024 Apr 10:e230375. doi: 10.1148/ryai.230375.
Radiol Imaging Cancer
- SPRAGUE BL, Nowak SA, Ahern TP, Herschorn SD, et al
Long-term Mammography Screening Trends and Predictors of Return to Screening
after the COVID-19 Pandemic: Results from a Statewide Registry.
Radiol Imaging Cancer. 2024;6:e230161.
- POLAT DS, Nguyen S, Karbasi P, Hulsey K, et al
Machine Learning Prediction of Lymph Node Metastasis in Breast Cancer:
Performance of a Multi-institutional MRI-based 4D Convolutional Neural Network.
Radiol Imaging Cancer. 2024;6:e230107.
Radiology
- LIU Y, Sorkhei M, Dembrower K, Azizpour H, et al
Use of an AI Score Combining Cancer Signs, Masking, and Risk to Select Patients
for Supplemental Breast Cancer Screening.
Radiology. 2024;311:e232535.
- KIM MK, Chang JM
AI-driven Selection of Candidates for Supplemental Breast Cancer Screening.
Radiology. 2024;311:e240447.
Semin Oncol
- SOBRINI-MORILLO P, Ravot C, Herledan C, Sanchez-Castellano C, et al
Real-world experience with CDK4-6 inhibition in the old and oldest old with a
diagnosis of breast cancer.
Semin Oncol. 2024 Feb 22:S0093-7754(24)00003.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016